Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schröder, Rudolf Trenschel, Miroslaw Markiewicz, Hélène Labussière-Wallet, Péter Reményi, Fabio Ciceri, Friedrich Stölzel

Blood (2023) 142 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2023-180816

Published: 2023

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe

Blood (2021) 138 (Supplement 1): 411.

https://doi.org/10.1182/blood-2021-153282

Published: 2021

Journal Articles

High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Christoph Groth, MD, Nina Kristin Steckel, MD, Jan-Henrik Mikesch, Rudolf Trenschel, MD, Hellmut Dietmar Ottinger, MD PhD, Carsten Müller-Tidow, Christoph Schliemann, Christian Reicherts, Eva Schmidt, Wolfgang E. Berdel, Georg Lenz, Markus Ditschkowski, Dietrich W Beelen, MD PhD, Matthias Stelljes, MD

Blood (2017) 130 (Supplement 1): 3205.

https://doi.org/10.1182/blood.V130.Suppl_1.3205.3205

Published: 2017

Journal Articles

Long-Term Efficacy of Reduced-Intensity Conditioning Compared to Standard Myeloablative Conditioning before Allogeneic Hemopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia in First Complete Remission: 10-Year Follow-up of a Prospective, Open-Label Randomized Phase III Trial

Blood (2017) 130 (Supplement 1): 4586.

https://doi.org/10.1182/blood.V130.Suppl_1.4586.4586

Published: 2017

Journal Articles

Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Dietrich W Beelen, MD PhD, Rudolf Trenschel, MD, Matthias Stelljes, MD, Tamás Masszi, MD Prof., Péter Reményi, Eva-Maria Maria Wagner-Drouet, MD, Peter Dreger, MD Prof., Wolfgang Bethge, MD Prof., Fabio Ciceri, MD, Friedrich Stoelzel, MD, Christian Junghanss, MD, Mauricette Michallet, MD Prof., Miroslaw Markiewicz, MD Prof.

Blood (2017) 130 (Supplement 1): 521.

https://doi.org/10.1182/blood.V130.Suppl_1.521.521

Published: 2017

Journal Articles

Reduced Relapse Risk In Patients With AML After Hhcmv-Replication Post Transplantation-First Results Of a Prospective Registration Trial

Ahmet H. Elmaagacli, MD, Nina-Kristin Steckel, MD, Meltem Kekec, Rudolf Trenschel, Markus Ditschkowski, MD, Tanja Gromke, Sandra Christoph, Hellmut Ottinger, MD, Dietrich Beelen, Michael Koldehoff, MD

Blood (2013) 122 (21): 5503.

https://doi.org/10.1182/blood.V122.21.5503.5503

Published: 2013

Journal Articles

Comparison Of Different Pretransplant Predictive Scores In Patients With Refractory Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Including Highdose Melphalan: Results Of a Double-Center Observational Study

Nina Kristin Steckel, M.D., Markus Ditschkowski, MD, Christoph Groth, M.D., Gerda Silling, MD, U. Krug, MD, Rudolf Trenschel, MD, Hellmut Ottinger, MD, Wolfgang E Berdel, MD, Michael Koldehoff, MD, Ahmet H. Elmaagacli, Dietrich Beelen, MD, Matthias Stelljes, MD

Blood (2013) 122 (21): 4525.

https://doi.org/10.1182/blood.V122.21.4525.4525

Published: 2013

Journal Articles

Human Chorionic Gonadotropin Hormone Induces Indoleamine 2,3-Dioxygenase and Interleukin-10 Expression In Patients With Graft-Versus-Host-Disease

Ahmet H. Elmaagacli, MD, Markus Ditschkowski, MD, Nina-Kristin Steckel, MD, Hellmut Ottinger, MD, Uwe Hillen, MD, Rudolf Trenschel, Dietrich Beelen, MD, Michael Koldehoff, MD

Blood (2013) 122 (21): 911.

https://doi.org/10.1182/blood.V122.21.911.911

Published: 2013

Journal Articles

Different Panel of Gene Variants Influence Outcome of Transplant From Sibling Donors Compared to HLA-Identical Unrelated Donors

Ahmet H Elmaagacli, MD, PhD, Michael Koldehoff, MD, Nina Kristin Steckel, Markus Ditschkowski, Rudolf Trenschel, MD, Hellmut Ottinger, Dietrich W. Beelen, MD

Blood (2012) 120 (21): 4182.

https://doi.org/10.1182/blood.V120.21.4182.4182

Published: 2012

Journal Articles

KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.

Sebastian Michaelis, cand.med., Markus Mezger, PhD, Martin Bornhauser, MD, Rudolf Trenschel, Gernot Stuhler, MD, Matthias Stelljes, MD, Lutz P Mueller, MD, Herrad Baurmann, MD, Birgit Federmann, MD, Lena Oevermann, MD, Lothar Kanz, MD, Rupert Handgretinger, MD, Wolfgang A. Bethge, MD

Blood (2012) 120 (21): 3101.

https://doi.org/10.1182/blood.V120.21.3101.3101

Published: 2012

Journal Articles

Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL),

Michael Schmitt, Rudolf Trenschel, MD, Herbert G. Sayer, MD, PhD, Catarina Schneider, Aenne Glass, Inken Hilgendorf, Anne Treschl, MD, Christian Junghanss, MD, Kersten Borchert, Michael Koenigsmann, Jochen Casper, MD, Dietrich Beelen, Mathias Freund, Christoph Kahl

Blood (2011) 118 (21): 4106.

https://doi.org/10.1182/blood.V118.21.4106.4106

Published: 2011

Journal Articles

Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial

Katja Sockel, MD, Jochen Greiner, MD, Rudolf Trenschel, MD, Christian Unzicker, MD, Guido Kobbe, MD, Jürgen Finke, MD, Ulrich Germing, MD, Brigitte Mohr, Dietrich Beelen, Gerhard Ehninger, MD, Martin Bornhaeuser, Uwe Platzbecker, MD

Blood (2011) 118 (21): 3060.

https://doi.org/10.1182/blood.V118.21.3060.3060

Published: 2011

Journal Articles

An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission

Blood (2011) 118 (21): 157.

https://doi.org/10.1182/blood.V118.21.157.157

Published: 2011

Journal Articles

Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients

Ahmet H. Elmaagacli, Nina K. Steckel, Michael Koldehoff, Yael Hegerfeldt, Rudolf Trenschel, Markus Ditschkowski, Sandra Christoph, Tanja Gromke, Lambros Kordelas, Hellmut D. Ottinger, Rudolf S. Ross, Peter A. Horn, Susanne Schnittger, Dietrich W. Beelen

Blood (2011) 118 (5): 1402–1412.

https://doi.org/10.1182/blood-2010-08-304121

Published: 2011

Journal Articles

Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis

Uwe Platzbecker, Johannes Schetelig, Juergen Finke, Rudolf Trenschel, Bart Lee Scott, Guido Kobbe, Kerstin Schaefer-Eckhart, Martin Bornhäuser, Raphael Itzykson, Ulrich Germing, Dietrich Beelen, Gerhard Ehninger, Pierre Fenaux, MD, PhD, H. Joachim Deeg, Lionel Ades

Blood (2010) 116 (21): 3500.

https://doi.org/10.1182/blood.V116.21.3500.3500

Published: 2010

Journal Articles

A Cytomegalovirus Reactivation Is Associated with An Improved Progression-Free Survival Rate In Patients with Lymphoma After Allogeneic Transplant

Ahmet H Elmaagacli, Sandra Christoph, Michael Koldehoff, MD, Nina Steckel, Rudolf Trenschel, Hellmut Ottinger, Dietrich Beelen

Blood (2010) 116 (21): 4912.

https://doi.org/10.1182/blood.V116.21.4912.4912

Published: 2010

Journal Articles

Toll-Like-Receptor Expression and Cellular Immune Reconstitution In AML-Patients with Elevated Serum Ferritin Levels After Allogeneic transplant.

Ahmet Elmaagacli, Nina Steckel, Michael Koldehoff, MD, Sandra Christoph, Hellmut Ottinger, Rudolf Trenschel, Dietrich Beelen

Blood (2010) 116 (21): 1049.

https://doi.org/10.1182/blood.V116.21.1049.1049

Published: 2010

Journal Articles

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

Wolfgang A. Bethge, Thoralf Lange, Christoph Meisner, Stephanie von Harsdorf, Martin Bornhaeuser, Birgit Federmann, Michael Stadler, Lutz Uharek, Matthias Stelljes, Stefan Knop, Gerald Wulf, Rudolf Trenschel, Vladan Vucinic, Helmut Dittmann, Christoph Faul, Wichard Vogel, Lothar Kanz, Donald Bunjes

Blood (2010) 116 (10): 1795–1802.

https://doi.org/10.1182/blood-2010-02-270538

Published: 2010

Journal Articles

No influence of gene polymorphism of LCT (C13910T) on transplantation outcomes in acute myeloid leukemia patients who received transplantations from HLA-identical sibling donors

Ahmet H. Elmaagacli, Nina Steckel, Markus Ditschkowski, Yael Hegerfeldt, Hellmut Ottinger, Rudolf Trenschel, Dietrich W. Beelen

Blood (2010) 115 (17): 3644–3645.

https://doi.org/10.1182/blood-2010-02-267443

Published: 2010

Journal Articles

Supportive Care Only Versus Allogeneic Hematopoietic Cell Transplantation in Patients ≥ 60 Years with De Novo High-Risk MDS.

Uwe Platzbecker, Jürgen Finke, Rudolf Trenschel, Schaefer-Eckart Kerstin, Martin Bornhauser, Guido Kobbe, Bart L Scott, Gerhard Ehninger, Dietrich Beelen, H. J. Deeg, Ulrich Germing

Blood (2009) 114 (22): 596.

https://doi.org/10.1182/blood.V114.22.596.596

Published: 2009

NARROW

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Long-Term Efficacy of Reduced-Intensity Conditioning Compared to Standard Myeloablative Conditioning before Allogeneic Hemopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia in First Complete Remission: 10-Year Follow-up of a Prospective, Open-Label Randomized Phase III Trial

Reduced Relapse Risk In Patients With AML After Hhcmv-Replication Post Transplantation-First Results Of a Prospective Registration Trial

Comparison Of Different Pretransplant Predictive Scores In Patients With Refractory Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Including Highdose Melphalan: Results Of a Double-Center Observational Study

Human Chorionic Gonadotropin Hormone Induces Indoleamine 2,3-Dioxygenase and Interleukin-10 Expression In Patients With Graft-Versus-Host-Disease

Different Panel of Gene Variants Influence Outcome of Transplant From Sibling Donors Compared to HLA-Identical Unrelated Donors

KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.

Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL),

Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial

An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission

Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients

Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis

A Cytomegalovirus Reactivation Is Associated with An Improved Progression-Free Survival Rate In Patients with Lymphoma After Allogeneic Transplant

Toll-Like-Receptor Expression and Cellular Immune Reconstitution In AML-Patients with Elevated Serum Ferritin Levels After Allogeneic transplant.

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

No influence of gene polymorphism of LCT (C13910T) on transplantation outcomes in acute myeloid leukemia patients who received transplantations from HLA-identical sibling donors

Supportive Care Only Versus Allogeneic Hematopoietic Cell Transplantation in Patients ≥ 60 Years with De Novo High-Risk MDS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only